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Abstract
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [39]) are
activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28
aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some
typical peptide modifications [102]. Currently the only orexin receptor ligand in clinical use is suvorexant, which is
used as a hypnotic. Orexin receptor crystal structures have been solved [124, 123].
Contents
This is a citation summary for Orexin receptors in the Guide to Pharmacology database (GtoPdb). It exists
purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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